Eli Lilly (LLY) is a global pharmaceutical company with over $23 billion in annual revenues, asserts...
Achillion Pharmaceuticals (ACHN): 2019 Top Picks' Mid-Year Update
07/17/2019 5:00 am EST
Bill Mathews, founder and contributing editor to The Cheap Investor, selected Achillian Pharmaceuticals (ACHN) as a more speculative idea for 2019. The stock has risen 69%. Here's his latest update on this biotech firm.
More from Bill Mathews: Biotech Bets (and a Goodbye) from a Favorite Expert
Achillion Pharmaceuticals has been a great investment. It is a clinical-stage biopharmaceutical company focused on advancing its oral small molecule complement inhibitors into late-stage development and commercialization.
Research has shown that an overactive complement system plays a critical role in multiple disease conditions including the therapeutic areas of nephrology, hematology, ophthalmology and neurology.
The company is initially focusing its drug development activities on complement-mediated diseases where there are no approved therapies or where existing therapies are inadequate for patients.
I continue to like Achillion because they have several products in FDA Trials. Their pipeline includes four products in late stage II and two products in stage I. They have a huge amount of cash $254 million.
Currently, 133 institutions own 80% of the float and the top nine institutions purchased 13.5 million more shares than they sold for the quarter ended March 30. Even though I think the stock has the potential of going higher, investors should protect their profits with stop loses.
Related Articles on HEALTHCARE
Ovarian cancer is the fifth leading cause of cancer-related deaths among U.S. women and is regarded ...
Viemed Healthcare (VMD), through its wholly owned subsidiaries Sleep Management and Home Sleep, is a...
Zoetis (ZTS) is among the top global companies in the discovery, development, manufacture, and marke...